Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
sulfasalazine
|
| gptkbp:brand |
gptkb:Azulfidine
|
| gptkbp:clinicalTrials |
pediatric use
long-term safety combination therapy with methotrexate comparison with mesalamine efficacy in rheumatoid arthritis efficacy in ulcerative colitis |
| gptkbp:contraindication |
porphyria
liver toxicity kidney damage severe liver disease severe renal impairment intestinal obstruction sulfa allergy bone_marrow_suppression |
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
true
anti-inflammatory |
| gptkbp:endOfLife |
7 to 12 hours
|
| gptkbp:formulation |
enteric-coated tablet
|
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:healthcare |
liver function tests
complete blood count renal function tests |
| https://www.w3.org/2000/01/rdf-schema#label |
Azulfidine EN-tabs
|
| gptkbp:interactsWith |
warfarin
methotrexate azathioprine |
| gptkbp:lastProduced |
1968
|
| gptkbp:mandates |
Crohn's disease
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:packaging |
bottle
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
headache
nausea diarrhea rash |
| gptkbp:skills |
500 mg
|
| gptkbp:storage |
room temperature
|
| gptkbp:threats |
asthma
hypersensitivity reactions G6PD deficiency |
| gptkbp:triggerType |
inhibits leukotriene synthesis
|
| gptkbp:type |
sulfasalazine
|
| gptkbp:usedFor |
treatment of rheumatoid arthritis
treatment of ulcerative colitis |
| gptkbp:waterManagement |
urine
|